Evidence map›Paper›PMID 35759503›Full record

ArticlePloS one2022

Genome sequence diversity of SARS-CoV-2 obtained from clinical samples in Uzbekistan.

Alisher Abdullaev, Abrorjon Abdurakhimov, Zebinisa Mirakbarova, Shakhnoza Ibragimova, Vladimir Tsoy, Sharofiddin Nuriddinov, Dilbar Dalimova, Shahlo Turdikulova, Ibrokhim Abdurakhmonov

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alisher AbdullaevCenter for Advanced Technologies, Tashkent, Uzbekistan.ORCID 0000-0002-8268-7699
Abrorjon AbdurakhimovCenter for Advanced Technologies, Tashkent, Uzbekistan.
Zebinisa MirakbarovaCenter for Advanced Technologies, Tashkent, Uzbekistan.
Shakhnoza IbragimovaCenter for Advanced Technologies, Tashkent, Uzbekistan.
Vladimir TsoyCenter for Advanced Technologies, Tashkent, Uzbekistan.
Sharofiddin NuriddinovCenter for Advanced Technologies, Tashkent, Uzbekistan.ORCID 0000-0002-4983-1695
Dilbar DalimovaCenter for Advanced Technologies, Tashkent, Uzbekistan.
Shahlo TurdikulovaCenter for Advanced Technologies, Tashkent, Uzbekistan.
Ibrokhim AbdurakhmonovCenter for Advanced Technologies, Tashkent, Uzbekistan.ORCID 0000-0001-9563-0686

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tracking temporal and spatial genomic changes and evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are among the most urgent research topics worldwide, which help to elucidate the coronavirus disease 2019 (COVID-19) pathogenesis and the effect of deleterious variants. Our current study concentrates genetic diversity of SARS-CoV-2 variants in Uzbekistan and their associations with COVID-19 severity. Thirty-nine whole genome sequences (WGS) of SARS-CoV-2 isolated from PCR-positive patients from Tashkent, Uzbekistan for the period of July-August 2021, were generated and further subjected to further genomic analysis. Genome-wide annotations of clinical isolates from our study have revealed a total of 223 nucleotide-level variations including SNPs and 34 deletions at different positions throughout the entire genome of SARS-CoV-2. These changes included two novel mutations at the Nonstructural protein (Nsp) 13: A85P and Nsp12: Y479N, which were unreported previously. There were two groups of co-occurred substitution patterns: the missense mutations in the Spike (S): D614G, Open Reading Frame (ORF) 1b: P314L, Nsp3: F924, 5`UTR:C241T; Nsp3:P2046L and Nsp3:P2287S, and the synonymous mutations in the Nsp4:D2907 (C8986T), Nsp6:T3646A and Nsp14:A1918V regions, respectively. The "Nextstrain" clustered the largest number of SARS-CoV-2 strains into the Delta clade (n = 32; 82%), followed by two Alpha-originated (n = 4; 10,3%) and 20A (n = 3; 7,7%) clades. Geographically the Delta clade sample sequences were grouped into several clusters with the SARS-CoV genotypes from Russia, Denmark, USA, Egypt and Bangladesh. Phylogenetically, the Delta isolates in our study belong to the two main subclades 21A (56%) and 21J (44%). We found that females were more affected by 21A, whereas males by 21J variant (χ2 = 4.57; p ≤ 0.05, n = 32). The amino acid substitution ORF7a:P45L in the Delta isolates found to be significantly associated with disease severity. In conclusion, this study evidenced that Identified novel substitutions Nsp13: A85P and Nsp12: Y479N, have a destabilizing effect, while missense substitution ORF7a: P45L significantly associated with disease severity.

Indexed as

COVID-19SARS-CoV-2FemaleGenome, ViralHumansMaleMutationOpen Reading FramesPhylogenySpike Glycoprotein, CoronavirusUzbekistanSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35759503
PMCPMC9236271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.